- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types - - Differentiated Safety Profile Continues to Emerge - SOUTH SAN FRANCISCO, Calif. , June 01, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical

SOUTH SAN FRANCISCO, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced

SOUTH SAN FRANCISCO, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced

Company to Host a Conference Call Today, May 9, 2019, at 5:00 p.m. EDT / 2:00 p.m. PDT SOUTH SAN FRANCISCO, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational

SOUTH SAN FRANCISCO, Calif. , May 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced

-Teleconference Scheduled for May 9, 2019, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on

SOUTH SAN FRANCISCO, Calif. , April 22, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

- PROCLAIM-CX-2009 Dose Escalation Study Demonstrates Anti-Tumor Activity in Multiple Tumor Types - - Preclinical Studies Suggest Role of CD166 Expression Level in Anti-Cancer Activity and Potential for Combination of CX-2009 with Immunotherapy - SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced